Abstract
Human transferrin receptor 1 (TfR1) is expressed on malignant cells at levels several fold higher than those on normal cells and its expression can be correlated with tumor stage or cancer progression. It is a potentially rational target for drug delivery. To identify novel ligands which can recognize the TfR1 specifically, a random phage displayed 12-mer peptide library was screened and two consensus motifs of the peptides which are displayed by the positive phages RXR and RXXXR (x is any amino acid) were yield. The phage displaying peptide SPRPRHTLRLSL (designated as B18) exhibited the highest affinity to TfR1 in phage ELISA and B18 could bind to TfR1 specifically in a dose dependent manner. The flow cytometry assay and immunocellularchemistry assay showed that the B18 could bind to TfR1 positive carcinoma cells with specificity. In addition, the biodistribution assay indicated that B18 could home to TfR1 positive tumor tissue specifically. Our study suggests that the peptide exhibited by B18 is a potentially promising targeting peptide for tumor diagnosis and treatment.
Keywords: TfR1, phage display, peptide, malignant cells, normal cells, tumor, cancer progression, flow cytometry assay
Protein & Peptide Letters
Title:Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug
Volume: 20 Issue: 1
Author(s): Qin Xin, Zhang Cun, Xue Xiaochang, Li Meng, Li Weina, Hao Qiang, Zhang Yingqi, Yan Zhen and Zhang Wei
Affiliation:
Keywords: TfR1, phage display, peptide, malignant cells, normal cells, tumor, cancer progression, flow cytometry assay
Abstract: Human transferrin receptor 1 (TfR1) is expressed on malignant cells at levels several fold higher than those on normal cells and its expression can be correlated with tumor stage or cancer progression. It is a potentially rational target for drug delivery. To identify novel ligands which can recognize the TfR1 specifically, a random phage displayed 12-mer peptide library was screened and two consensus motifs of the peptides which are displayed by the positive phages RXR and RXXXR (x is any amino acid) were yield. The phage displaying peptide SPRPRHTLRLSL (designated as B18) exhibited the highest affinity to TfR1 in phage ELISA and B18 could bind to TfR1 specifically in a dose dependent manner. The flow cytometry assay and immunocellularchemistry assay showed that the B18 could bind to TfR1 positive carcinoma cells with specificity. In addition, the biodistribution assay indicated that B18 could home to TfR1 positive tumor tissue specifically. Our study suggests that the peptide exhibited by B18 is a potentially promising targeting peptide for tumor diagnosis and treatment.
Export Options
About this article
Cite this article as:
Xin Qin, Cun Zhang, Xiaochang Xue, Meng Li, Weina Li, Qiang Hao, Yingqi Zhang, Zhen Yan and Wei Zhang, Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug, Protein & Peptide Letters 2013; 20 (1) . https://dx.doi.org/10.2174/0929866511307010096
DOI https://dx.doi.org/10.2174/0929866511307010096 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Preface
Current Molecular Medicine Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Occurrence and Biological Properties of Sphingolipids - A Review
Current Nutrition & Food Science Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design ATP Site-Directed Inhibitors of Protein Kinase CK2: An Update
Current Topics in Medicinal Chemistry Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Detection of Natural Inhibitors against Human Liver Cancer Cell Lines through QSAR, Molecular Docking and ADMET Studies
Current Topics in Medicinal Chemistry Electric cable: cytoskeleton as an electric transmitter for cancer therapy
Current Signal Transduction Therapy Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Blocking HIV-1 Vif Restores a Natural Mechanism of Intracellular Antiviral Defense
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology Tumor Promoters - Microcystin-LR, Nodularin and TNF-α and Human Cancer Development
Anti-Cancer Agents in Medicinal Chemistry HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Protease Inhibitors in the Clinic
Medicinal Chemistry Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry